Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Medicare Formulary Coverage Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentpriority healthPolicy N/A

    Priority Health Medicare 2026 Formulary (Drug List) - Coverage Criteria

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the Priority Health Medicare formulary (Drug List) that describes covered prescription drugs, coverage rules (prior authorization, step therapy, quantity limits), member rights to exceptions and transition supplies, and how to use the formulary. It affects Priority Health Medicare members, prescribers, and network pharmacies.

    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare 2026 Formulary (Drug List) - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewMay 21, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug entry lists 'PA' to avoid denial of coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026formulary year
    Jun 1formulary current as of
    30 daysmid-year notice
    72 hrsexception decision time
    PA/QL/STutilization types

    Coverage Criteria & Exceptions

    inv-01: General Coverage and Exceptions

    Covered when ALL of the following are met:

    Formulary coverage conditions: Priority Health Medicare will generally cover drugs listed on the formulary when the drug is medically necessary, the prescription is filled at a Priority Health Medicare network pharmacy, and other plan rules are followed.

    source: chunk 3

    Member options if drug not covered or restricted: Member may (1) contact Customer Care for covered alternatives, (2) request a formulary or tiering exception (prescriber must supply medical rationale), or (3) receive a temporary transition supply while pursuing an exception or alternative therapy.

    source: chunks 12,15

    Exception decision timing: When a prescriber submits supporting clinical information for an exception, Priority Health Medicare generally must decide within 72 hours; expedited requests (when waiting could seriously harm the member) are decided within 24 hours.
    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare 2026 Formulary (Drug List) - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewMay 21, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug entry lists 'PA' to avoid denial of coverage.
    SourceLink
    On This Page
    Coverage Criteria & ExceptionsFormulary Drug Entries & CodesProvider Actions, Prior Authorization & DocumentationSite of Care Designations (Home Infusion / Infusion Center)Step Therapy Rules & ExamplesQuantity Limits (QL) — Selected ExamplesDefinitions & AbbreviationsBiosimilars & SubstitutionBackground NotesAdditional Coding & Legend Notes
    72 hours (standard); 24 hours (expedited)

    source: chunk 14

    inv-02: Mid-year Changes and Member Notice

    Mid-year formulary change rules include the following scenarios and member notice requirements:

    Immediate changes allowed (generics/biosimilars): The plan may immediately add a new generic or certain biosimilars and, when adding such versions, may remove or move the existing brand/original biological product to the same or a different tier or add restrictions without advance notice to affected members; members or prescribers may request an exception.

    source: chunk 4

    Withdrawn for safety or removed from market: If a drug is withdrawn from sale by the manufacturer or removed by FDA for safety/effectiveness, the drug may be removed immediately from the formulary; affected members will be notified later.

    source: chunk 5

    Notice for other mid-year changes: For other mid-year changes (removal, addition of PA/QL/ST, or tier changes), the plan must notify affected members at least 30 days before the change or, alternatively, provide a 30-day supply at the next refill with notice.30 days notice or 30-day supply at refill

    source: chunk 5

    Stable-coverage assurance during coverage year: Drugs covered at the start of the coverage year generally will not have coverage discontinued or reduced during the coverage year except as described (e.g., market withdrawal or biosimilar substitution).

    source: chunk 6

    inv-03: Transition Supply Rules

    Transition and temporary coverage when a member's prescribed drug is non-formulary or restricted:

    Initial member transition supply: For each drug not on the formulary or with a coverage restriction, Priority Health Medicare will cover a temporary 30-day supply (or fewer days if the prescription is written for fewer days) while the member and prescriber pursue an exception or alternative therapy during the first 90 days of membership.30 days (general); 90 days (membership period)

    source: chunk 15

    Refill limitation after transition supply: If coverage is not approved after the initial transition supply, the plan will not pay for further fills even if the member remains within the first 90 days, unless an exception is granted.

    source: chunk 15

    Long-term care emergency supply: For long-term care facility residents past the first 90 days of membership who need a non‑formulary drug or have limited access, the plan will cover a 31‑day emergency supply while the member pursues a formulary exception.31 days (LTC emergency)

    source: chunk 15

    Transition supply for level-of-care change: Members experiencing a change in level of care will receive a transition supply of at least 30 days of medication unless the prescription is written for fewer days.30 days

    source: chunk 15

    inv-04: Covered with conditions

    Coverage is provided with specified utilization management requirements when listed in the formulary Requirements/Limits column:

    Tier-based coverage: A drug's coverage follows its assigned formulary tier (T1–T5); when Requirements/Limits (PA, QL, ST, HI, LA, NE) are shown for a drug, those controls must be met for coverage to be paid.

    source: chunks 56,59,63

    Prior Authorization (PA): When a product's Requirements/Limits lists PA, coverage requires prior authorization approval from Priority Health Medicare before the drug will be covered.

    source: chunks 63,72

    Quantity Limits (QL): When QL is listed, dispensing is limited to the numeric quantity and time period specified for that product (examples vary by product and formulation).e.g., QL values provided per product entry

    source: chunks 59,71,72

    Step Therapy (ST): When ST is listed, the member must meet step therapy requirements (trial/failure of specified alternatives) before coverage of the requested drug is provided.

    source: chunks 59,63,67

    Home Infusion / Site-of-care (HI) and Limited Availability (LA): Entries marked HI or LA indicate home‑infusion or limited‑availability handling that may affect coverage channel or supply and must be followed for coverage.

    source: chunks 56,63,67

    inv-05: Coverage Stance: Specialty/Oncology drugs with PA and QL

    Specialty and oncology agents are generally covered only when specific utilization controls are met:

    Specialty-tier controls: Most specialty (Tier 5) and many oncology drugs listed require prior authorization and have quantity limits specified by strength/packaging; Tier 5 drugs are 30‑day supply only per the formulary note.30-day supply limit for Tier 5 drugs

    source: chunks 90,94,101

    PA and QL examples: Examples of listed controls include KISQALI FEMARA (Requirements/Limits = PA; QL 49 EA per 28 days) and LUMAKRAS 120 mg (Requirements/Limits = PA; QL 240 EA per 30 days); prescribers must obtain PA where indicated.

    source: chunk 90

    inv-06: Coverage controls (PA, QL, B/D)

    Per‑product formulary entries specify controls that must be satisfied for coverage:

    Prior authorization requirement for PA-coded drugs: When an item’s Requirements/Limits field lists 'PA', the plan requires prior authorization approval before coverage will be provided.

    source: chunks 234-237

    Quantity limits enforcement for QL-coded drugs: When an item’s Requirements/Limits field lists 'QL', dispensing is restricted to the stated quantity per the specified time period for that product (formulation-specific QL values appear in the formulary entries).e.g., 0.2–8 mL per 28 days; 2.4 mL per 28 days; 4 EA per 28 days

    source: chunks 234-239

    Part B vs Part D designation (B/D): Entries marked 'B/D' indicate the product may be billed under Medicare Part B or Part D depending on use/setting; this designation affects benefit responsibility and may require additional provider documentation.

    source: chunks 234,236,239

    inv-07: Utilization control criteria (formulary-level)

    Formulary-level utilization controls (these controls, when present on an entry, may trigger coverage restrictions):

    Applicable controls: Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), Limited Availability (LA), and B/D designations are applied on a per‑drug basis as shown in formulary entries; presence of any of these requires compliance with the listed process or limits for coverage.

    source: chunks 262-265

    Examples of control combinations: Examples include CAYSTON (PA; LA), KALYDECO (PA; QL 56 EA per 28 days), TRIKAFTA (PA; QL 84 EA per 28 days), OFEV (PA; QL 60 EA per 30 days; LA) — each listed control must be met for coverage.

    source: chunks 262-264

    Denial risk if controls not met: Claims for drugs listed with PA or exceeding QL and other specified controls may be denied if the prior authorization is not obtained or dispensing exceeds the stated quantity/timeframe.

    source: chunks 262-265

    The formulary defines ED (Excluded Drug) as a prescription drug that is not normally covered in a Medicare Prescription Drug Plan. Amounts a member pays for an ED do not count toward their total drug costs for qualification toward catastrophic coverage, and members receiving extra help will not receive that extra help for EDs. Coverage for EDs is only available on Priority Medicare® Thrive and Thrive Plus plans.

    Excluded drugs are identified in the formulary abbreviations as ED — Excluded Drug. Per the formulary, costs for these drugs do not count toward catastrophic coverage, and coverage is limited to specific Priority Medicare plan variants (Priority Medicare® Thrive and Thrive Plus).

    The formulary abbreviation legend and keys use the marking NE (No Express Scripts) and ED (Excluded Drug) to annotate items in the drug list; these markers are included in the document legend for provider reference.

    Some formulary entries and the legend include flags such as NE and ED, indicating restricted sourcing (NE) or exclusion from Medicare Part D coverage (ED) where specified. Entries that carry these flags should be handled according to the legend and any per‑drug Requirements/Limits noted.

    In the chunks cited here the document defines the abbreviation ED and shows it in the legend, but these excerpts do not list a drug‑level catalog of specific excluded drugs. The excerpts therefore reference the concept of excluded drugs without enumerating which products are excluded.

    The formulary legend explicitly includes the definition ED — Excluded Drug, so reviewers should note that an ED designation exists in the document even though specific excluded drug listings are not shown in these particular chunks.

    Although the document text defines ED (Excluded Drug) in the abbreviations/legend, the provided segments do not show explicit drug entries marked ED; the legend presence indicates ED may appear elsewhere in the full formulary.

    Formulary Drug Entries & Codes

    NSAIDs (selected)mixedCovered
    diclofenac_sodium_erdiclofenac sodium ER (oral)
    diclofenac_sodium_external_1.5%diclofenac sodium external solution 1.5% (QL 750 ML/30 days)
    diclofenac_oral_delayed_50mgdiclofenac sodium oral tablet delayed release 50 mg, 75 mg
    diclofenac_potassium_50mg_tabletdiclofenac potassium oral tablet 50 mg
    celecoxib_oralcelecoxib oral
    Beta-Lactam / PenicillinsmixedCovered
    amoxicillin_oral_capsuleamoxicillin oral capsule/tablet/suspension (multiple strengths)
    ampicillin_oral_capsule_500mgampicillin oral capsule 500 mg
    ampicillin_sodium_inj_1gmampicillin sodium injection solution reconstituted 1 gm (HI)
    ampicillin_sodium_iv_10gmampicillin sodium intravenous solution reconstituted 10 gm (HI)
    ampicillin_sulbactam_3_2-1_gmampicillin-sulbactam sodium injection solution reconstituted 3 (2-1) gm (HI)
    ampicillin_sulbactam_15_10-5_gmampicillin-sulbactam sodium intravenous solution reconstituted 15 (10-5) gm (HI)
    penicillin_g_pot_in_dextrose_40000u_mlpenicillin G pot in dextrose IV solution 40000 unit/ml (HI)
    penicillin_g_potassium_inj_20000000upenicillin G potassium injection solution reconstituted 20000000 unit (HI)
    penicillin_g_potassium_inj_5000000upenicillin G potassium injection solution reconstituted 5000000 unit
    Antipseudomonal / Beta-Lactam Combos & CarbapenemsmixedCovered
    piperacillin_tazobactam_2.25_3.375_4.5_40.5_gmpiperacillin-sodium tazobactam IV solution reconstituted 2.25 (2-0.25) gm; 3.375 (3-0.375) gm; 4.5 (4-0.5) gm; 40.5 (36-4.5) gm (HI)
    cefazolin_injcefazolin sodium injection solution reconstituted (various gm/500 mg) (HI)
    ceftriaxone_inj_1gm_2gm_250mg_500mgceftriaxone sodium injection solution reconstituted 1 gm, 2 gm, 250 mg, 500 mg (HI)
    ertapenem_sodiumertapenem sodium
    imipenem_cilastatinimipenem-cilastatin
    meropenem_iv_1gm_500mgmeropenem intravenous solution reconstituted 1 gm, 500 mg
    Quinolones & RelatedmixedCovered
    ciprofloxacin_ophthalmic_oral_ivciprofloxacin ophthalmic; oral tablets 250 mg, 500 mg, 750 mg; IV (ciprofloxacin in D5W 200 mg/100 ml)
    moxifloxacin_iv_oralmoxifloxacin IV (HI) and oral formulations
    levofloxacin_iv_orallevofloxacin IV in D5W 500 mg/100 ml, 750 mg/150 ml; oral tablets/solution
    Sulfonamides & TetracyclinesmixedCovered
    sulfamethoxazole_trimethoprim_suspension_200-40_5mlsulfamethoxazole-trimethoprim oral suspension 200-40 mg/5 ml
    sulfamethoxazole_trimethoprim_tabletsulfamethoxazole-trimethoprim oral tablet
    doxycycline_variousdoxycycline formulations: hyclate IV/oral capsule/tablet 100 mg, 20 mg; monohydrate capsules 100/50 mg; suspension/reconstituted forms
    minocycline_capsuleminocycline HCl oral capsule
    Anticonvulsants (selected) — standard & specialtymixedCovered
    brivaracetam_oral_solution_tabletbrivaracetam oral solution/tablet (PA; QL 600 ML solution / 60 EA tablets per 30 days)
    levetiracetam_variouslevetiracetam ER, oral solution, tablets, disintegrating tablets (PA and QL for certain disintegrating strengths)
    perampanel_tablets_suspensionperampanel oral tablets (2,4,6,8,10,12 mg) and oral suspension (PA; QL examples)
    cenobamate_XCOPRI_variousXCOPRI (cenobamate) multiple oral tablet formulations and therapy packs (PA; QL indicated)
    zonisamide_ZONISADEZONISADE (zonisamide) (PA; QL 900 ML per 30 days)
    ZTALMY_VIGAFYDEZTALMY; VIGAFYDE; other specialty anticonvulsants (PA; QL as specified)
    carbamazepine_phenytoin_oxcarbazepine_lacosamide_rufinamide_zonisamidesodium-channel and other anticonvulsants: carbamazepine (ER, suspension, tablet, chewable), phenytoin (suspension 125 mg/5 ml, chewable tablets, extended capsules), oxcarbazepine (suspension, tablets), lacosamide (oral solution 10 mg/ml, tablets), rufinamide (tablets/suspension), zonisamide
    Antidementia & Cognitive AgentsmixedCovered
    donepezil_galantamine_rivastigmine_memantinedonepezil (5,10,23 mg; dispersible options; QLs), galantamine hydrobromide (ER and tablets), rivastigmine (PA/QL for patch/tablet), memantine (oral solution 2 mg/ml; ER/tablet QLs)
    AUVELITY_EXXUA_ZURZUVAEAUVELITY; EXXUA (and TITRATION PACK); ZURZUVAE (capsules) — specialty antidepressant agents (PA; QL as noted)
    EMSAM_MARPLAN_MAOIsEMSAM (PA), MARPLAN (PA; QL 180 EA/30 days), other MAOIs
    Antidepressants — SSRIs/SNRIs & othersmixedCovered
    citalopram_hydrobromide_solution_tabletscitalopram hydrobromide oral solution (QL 600 ML/30 days) and tablets 10 mg, 20 mg, 40 mg (QLs)
    bupropion_mirtazapine_MISCbupropion ER, mirtazapine formulations
    ZURZUVAE_AUVELITY_EXXUAZURZUVAE, AUVELITY, EXXUA and other specialty antidepressants (PA; QL)
    Cardiovascular — Beta blockers & CCBs (selected)mixedCovered
    propranolol_hcl_er_solution_tabletpropranolol HCl ER (tier 2); propranolol HCl oral solution; propranolol HCl oral tablet
    felodipine_er_nifedipine_erfelodipine ER (tier 2); nifedipine ER (including osmotic release)
    diltiazem_er_beads_360_420mgdiltiazem HCl ER beads oral capsule extended release 24 hour 360 mg, 420 mg
    verapamil_er_capsule_tablet_24hverapamil HCl ER oral capsule extended release 24 hour 100 mg, 200 mg, 300 mg; other ER tablet strengths 120/180/240 mg
    Ophthalmic Anti-Infectives & Anti-InflammatoriesmixedCovered
    ciprofloxacin_ophthalmicciprofloxacin HCl ophthalmic
    moxifloxacin_ophthalmicmoxifloxacin HCl ophthalmic solution (QL 12 ML/30 days)
    bacitracin_ophthalmic_erythromycin_gentamicinbacitracin ophthalmic (QL 7 GM/30 days), erythromycin ophthalmic (QL 21 GM/30 days), gentamicin ophthalmic solution (QL 30 ML/30 days)
    diclofenac_sodium_ophthalmicdiclofenac sodium ophthalmic (anti-inflammatory)
    Cystic Fibrosis & Pulmonary Fibrosis AgentsmixedCovered
    tobramycin_inhalation_300mg_5mltobramycin inhalation nebulization solution 300 mg/5 ml (B/D)
    pulmozyme_2.5mg_2.5mlPULMOZYME inhalation solution 2.5 mg/2.5 ml (B/D)
    kalydeco_orkambi_trikaftaKALYDECO, ORKAMBI, TRIKAFTA and related CF modulators (PA; QLs as listed)
    nintedanib_pirfenidonenintedanib esylate (OFEV) and pirfenidone (PA; QLs)

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior Authorization Required

    Certain drugs on the formulary require Prior Authorization (PA) and some carry a B/D designation indicating Part B vs. Part D coverage differences. Providers must obtain prior authorization from Priority Health Medicare before dispensing drugs with PA; failure to obtain PA may result in claim denials or non-coverage. For B/D-designated products, clinicians may need to submit documentation describing the drug’s use and setting so the plan can determine whether Medicare Part B (medical benefit) or Part D (prescription drug benefit) applies.

    • PA = Prior Authorization (approval required before filling)
    • B/D = Part B vs. Part D (may affect coverage pathway and documentation)
    Documentation Required

    Prior Authorization Requirements

    Providers must obtain prior authorization for many specialty, non-preferred, infusion, home-infusion (HI) and certain high-cost agents listed in the formulary. When a Requirements/Limits field shows PA (and/or QL, ST, HI, LA), prescribers must submit supporting clinical documentation that justifies medical necessity and demonstrates that any specified criteria (including step therapy or prior trials of alternatives) have been met.

    • Prescriber statement should describe the medical indication, prior therapies tried (if applicable), and the care setting for B/D determinations
    • Expedited (72-hour to 24-hour) exception/appeal timelines apply when clinically necessary
    Prior Authorization

    Prior Authorization for Listed Drugs

    Prior authorization is required for many listed drugs and devices across therapeutic classes — examples from the formulary include: AUVELITY, EXXUA, ZURZUVAE, multiple anticonvulsants (brivaracetam, EPIDIOLEX), select oncology and molecular targeted agents (KISQALI, LUMAKRAS, LYNParZA), biologics and immunomodulators (DUPIXENT, COSENTYX, REPATHA), and numerous specialty injectables and infusion agents. Requirements/Limits entries in the formulary indicate PA, QL, ST, HI or LA as applicable.

    • Many specialty biologics and injectables show PA plus a quantity limit (QL)
    • Home infusion (HI) and Limited Availability (LA) items may have separate routing or site-of-care requirements
    Prior Authorization

    Prior Authorization Required for Drugs & Devices

    The formulary lists numerous drugs and devices that require prior authorization and/or have quantity limits or other limits. Examples include select diabetes pens/insulin supplies (pen needles, BD items), oncology agents, blood products and modifiers, cystic fibrosis agents, and many specialty self-injectable biologics. Consult the Requirements/Limits column for each product to determine whether PA (and associated QL, HI, LA, or B/D) applies.

    • Examples: pen needles and insulin supplies marked PA (see insulin supplies section)
    • Blood products (e.g., PROCRIT) marked B/D — coverage may differ by Part B vs Part D
    Prior Authorization

    Prior Authorization for Specialty/Biologic Drugs

    Many specialty, biologic and selected non-preferred agents require prior authorization; common examples include adalimumab products, ustekinumab, dupixent, cosentyx, humira, enbrel, and other monoclonal antibody and targeted therapies. For these agents, PA and QL values are commonly listed together; prescribers should confirm required dosing frequency and maximum covered amounts.

    • Biologics frequently show PA + QL (e.g., COSENTYX, DUPIXENT, SKYRIZI, REPATHA)
    • Many immunosuppressants/immunomodulators include B/D or PA annotations
    Prior Authorization

    Prior Authorization for Many Specialty/Biologic Agents

    Specialty and biologic agents across the formulary often require prior authorization and quantity limits. Providers must supply clinical rationale and prior-treatment history when requesting PA for these products. Anticipate additional documentation for home infusion (HI) or limited-availability (LA) items, and for B/D-designated drugs where site-of-care/use affects coverage determination.

    • Examples: XOLAIR, TRIKAFTA, KALYDECO, and many anti‑TNF/IL agents show PA (and some show B/D or LA)
    • Requests for HI-covered agents should note infusion setting and responsible clinician
    Denial Risk

    Authorization Triggers & Denials

    Prior authorization triggers include PA entries in the Requirements/Limits column, Step Therapy (ST) requirements, and Quantity Limits (QL). Claims may be edited or denied if the PA was not obtained, if QLs are exceeded, or if ST requirements were not met. Providers should verify formulary notes and the abbreviations legend before submitting prescriptions or claims.

    • Common triggers: PA, QL, ST, HI, LA, NE
    • Tier 5 (specialty) drugs are generally limited to 30-day supplies — see formulary note
    Denial Risk

    Authorization Denial Risk & Exception Process

    Failure to obtain required PA or to adhere to specified QLs or ST rules may result in claim denial or non‑coverage. Providers should document and submit the required supporting clinical information with PA requests. If an exception is needed, prescribers must explain why the formulary alternative is not appropriate; determinations are generally made within 72 hours (24 hours for expedited requests).

    • Exceptions allow waiver of PA, ST or QL when medical necessity is demonstrated
    • Expedited exception decisions available when delay could seriously harm the patient
    Documentation Required

    Prescriber Documentation Expectations

    Providers must include supporting clinical documentation for PA and exception requests: diagnosis, prior therapies/trials, rationale for use of the requested drug, dosing, and the site of administration (especially for B/D or HI items). The formulary’s Requirements/Limits column indicates what documentation is expected; adhere to quantity limits to avoid denials.

    • Include prescriber statement describing medical necessity when submitting exceptions or PA requests
    • Reference the formulary abbreviations (PA, QL, ST, HI, LA, B/D) on submissions
    Note

    Formulary Reference & Administrative Notes

    Formulary administrative notes and abbreviation keys appear in the formulary (see abbreviation legend and page references). Tier definitions (T1–T5), Tier 5 supply rules (30-day specialty supply only), and a legend for PA/QL/ST/B/D/HI/LA/NE are provided; providers should consult these references when preparing PA requests and when counseling patients about coverage and supply limits.

    • Abbreviation legend and tier definitions begin on page 9 of the formulary
    • Formulary updated 5/21/2026; effective policy date: 2026-06-01
    Billing Rule

    Quantity Limit Adherence

    Quantity limits (QL) are enforced for many products. Providers should follow the QL values shown in the Requirements/Limits column to avoid claim denials or edits. When higher quantities are clinically necessary, submit a PA with supporting rationale or request a formulary exception.

    • Examples: XARELTO 10 mg = QL 30 tablets per 30 days; many specialty injectables have ML or mL QLs
    • Tier 5 drugs are typically limited to 30-day supplies
    Documentation Required

    Required Documentation for PA and QL Items

    When the formulary entry specifies PA or QL, providers must supply the required documentation as noted in the Requirements/Limits field. This includes dosing schedule, prior treatment failures (for ST items), and site-of-care details for B/D or HI-designated drugs. Use the formulary product entry as the authoritative reference for what is required with each PA request.

    • Requirements/Limits fields are the operational source for PA, QL, ST, HI, LA and B/D requirements
    • Documentation submitted should directly address the criteria listed in the formulary entry
    Note

    Formulary Abbreviations & Submission Reference

    The formulary includes an abbreviation key (PA, QL, ST, B/D, HI, LA, NE, etc.) and tier definitions; prescribers should reference these abbreviations when submitting PA/exception requests. Abbreviation meanings and administrative instructions are found at the beginning of the formulary (see page references in the formulary).

    • PA = Prior Authorization; QL = Quantity Limit; ST = Step Therapy; B/D = Part B vs Part D
    • NE = No Express Scripts; HI = Home Infusion; LA = Limited Availability
    Step Therapy

    Step Therapy Requirements & Examples

    Step therapy (ST) is applied to certain agents and requires trial of specified formulary alternatives before coverage of the requested drug. Examples include DIFICID, FETZIMA, TRINTELLIX, vilazodone, and selected ophthalmic agents (travoprost bak‑free, difluprednate, loteprednol) which list ST in Requirements/Limits. The formulary legend and individual product entries indicate where ST applies.

    • ST examples: DIFICID oral forms (ST + QL), FETZIMA (ST + QL), TRINTELLIX (ST + QL)
    • Ophthalmic ST examples: travoprost (bak-free) and certain topical ophthalmic anti‑inflammatories

    Site of Care Designations (Home Infusion / Infusion Center)

    Billing Rule

    PA and site‑of‑care/B/D billing considerations for injectables

    Prescriptions for specialty injectables and certain biologics may require PA and the plan may determine Part B vs Part D (B/D); providers should contact Customer Care for site‑of‑care or billing pathway questions.

    • PROCRIT/RETACRIT entries show B/D — benefit/payment channel may vary.
    • Contact Customer Care for home infusion or B/D billing determinations.
    Billing Rule

    Contact Customer Care for HI (home infusion) authorization and coverage

    Some products designated 'HI' (Home Infusion) may be covered under the medical benefit rather than the pharmacy benefit; providers should contact Customer Care for authorization and site‑of‑care guidance.

    • HI designation appears on IV/infusion products (e.g., ceftazidime, ceftriaxone, vancomycin IV).
    • Customer Care contact provided for home infusion coverage details.
    Note
    Note
    Note
    Note
    Note

    Step Therapy Rules & Examples

    MechanismHigh-level note
    Step Therapy (ST)Requires trial of specified alternative drug(s) before coverage of another agent; plan may deny coverage if step requirements are not met.
    Applies toFormulary indication / per-drug note
    DIFICID (fidaxomicin)Requirements/Limits shows ST; QL (136 ML per 10 days for suspension; 20 EA per 10 days for tablet)
    Selected antidepressants (examples)FETZIMA, TRINTELLIX, vilazodone — Requirements/Limits shows ST (also QL where listed); NE noted for some entries
    Legend termMeaning / usage
    STStep Therapy — listed in formulary abbreviations/legend; indicates trial of specified drugs required before coverage of alternatives
    NoteLegend defines ST among other requirement codes (PA, QL, HI, LA, NE); specific step rules are provided per drug where present
    ProductST / Requirements
    DIFICID (oral suspension / tablet)Requirements/Limits = ST; QL (136 ML per 10 days for suspension; 20 EA per 10 days for tablet)
    ProductST / Requirements
    FETZIMARequirements/Limits = ST; QL (30 EA per 30 days); NE indicated for some entries
    TRINTELLIXRequirements/Limits = ST; QL (30 EA per 30 days); NE indicated for some entries
    vilazodoneListed with ST in Requirements/Limits (per antidepressant class entries)
    ReferenceDocument note
    Abbreviations / legendST (Step Therapy) appears in abbreviation lists/legend but specific step criteria are only shown on per-drug rows where applicable
    ProductST / Other controls
    paliperidone ER (various strengths)Requirements/Limits = ST; QL (e.g., 30 EA per 30 days for 1.5/3/9 mg; 60 EA per 30 days for 6 mg)
    Legend referenceExplanation
    ST in legendFormulary legend includes 'ST - Step Therapy' as a requirement/limit abbreviation; consult per-drug entries for application
    MechanismAvailability / note
    Step Therapy (ST)ST is an available formulary utilization management mechanism used alongside PA and QL to manage coverage; details are provided on drug-specific lines
    Reference locationComment
    Abbreviation lists (page references)ST appears with other abbreviations (PA, QL, HI, LA) in multiple abbreviation listings throughout the formulary
    Product / exampleST indicated
    calcitriol (external)Requirements/Limits = ST (step therapy applies) per dermatological/external product listing
    Legend entryMeaning
    ST - Step TherapyDefined in the abbreviations/legend as a utilization management requirement; per-drug application varies and is shown on individual entries
    ProductST / Requirements
    travoprost (BAK-free)Requirements/Limits = ST as listed in ophthalmic agents section
    ProductST / Requirements
    difluprednate (ophthalmic)Requirements/Limits = ST (step therapy applies)
    loteprednol (ophthalmic gel/suspension)Requirements/Limits = ST (step therapy applies)

    Quantity Limits (QL) — Selected Examples

    inv-135: XARELTO 10MG — example quantity per prescription
    XARELTO oral tablet 10 mgQL 30 tablets per prescription
    XARELTO oral suspension (reconstituted)QL 620 ML per 30 days
    inv-136: fentanyl transdermal patch QL example
    Fentanyl transdermal patch 72-hourQL 10 EA per 30 days
    Lidocaine external patch 5%PA; QL 90 EA per 30 days
    inv-137: buprenorphine transdermal QL example
    Buprenorphine transdermalQL 4 EA per 28 days
    Hydromorphone oral liquidQL 2400 ML per 30 days
    inv-138: XIFAXAN 550 mg QL example
    XIFAXAN 550 mg (oral tablet)PA; QL 60 EA per 30 days
    XIFAXAN 200 mg (oral tablet)PA; QL 9 EA per 30 days
    inv-139: vancomycin oral capsule 125 mg QL example
    Vancomycin HCl oral capsule 125 mgQL 80 EA per 30 days
    Vancomycin HCl oral capsule 250 mgQL 160 EA per 30 days
    inv-140: Multiple QL examples — assorted entries
    DIFICID oral suspension/tabletST; QL 136 ML per 10 days (suspension) or QL 20 EA per 10 days (tablet)
    Brivaracetam oral tabletPA; QL 60 EA per 30 days
    EPIDIOLEXPA; QL 500 ML per 30 days
    inv-141: AUVELITY QL example
    AUVELITYPA; QL 60 EA per 30 days
    EXXUAPA; QL 30 EA per 30 days
    inv-142: EXXUA QL example
    EXXUAPA; QL 30 EA per 30 days
    EXXUA Titration PackPA; QL 32 EA per 30 days
    inv-143: MARPLAN QL example
    MARPLANPA; QL 180 EA per 30 days
    EMSAMPA
    inv-144: AIMOVIG QL example
    AIMOVIGPA; QL 1 ML per 30 days
    EMGALITY (300 mg dose)PA; QL 3 ML per 30 days
    inv-145: EMGALITY (300 mg dose) QL example
    EMGALITY (300 mg dose)PA; QL 3 ML per 30 days
    EMGALITY (standard)PA; QL 2 ML per 30 days
    inv-146: KISQALI FEMARA (200 MG DOSE) QL example
    KISQALI FEMARA (200 mg)PA; QL 49 EA per 28 days
    LUMAKRAS 120 mgPA; QL 240 EA per 30 days
    inv-147: LUMAKRAS ORAL TABLET 120 MG QL example
    LUMAKRAS oral tablet 120 mgPA; QL 240 EA per 30 days
    LUMAKRAS 240 mgPA; QL 120 EA per 30 days
    inv-148: dasatinib oral tablet 100 mg QL example
    Dasatinib oral tablet 100 mgPA; QL 60 EA per 30 days
    Dasatinib other strengthsPA; QL 60 EA per 30 days (example)
    inv-149: VITRAKVI ORAL CAPSULE 100 MG QL example
    VITRAKVI oral capsule 100 mgPA; QL 60 EA per 30 days
    VITRAKVI oral solutionPA; QL 300 ML per 30 days
    inv-150: COARTEM QL example
    COARTEMQL 24 EA per 30 days
    Other antimalarial entriesQL values vary by product
    inv-151: abilify asimtufii IM syringe QL example (ML per 56 days)
    Abilify asimtufii IM 720 mg/2.4mlQL 2.4 ML per 56 days
    Abilify asimtufii 960 mg/3.2mlQL 3.2 ML per 56 days
    inv-152: ABILIFY MAINTENA IM QL example
    ABILIFY MAINTENA intramuscular prefilled syringeQL 1 EA per 30 days
    ABILIFY MAINTENA suspension reconstituted ERQL 1 EA per 30 days
    inv-153: INVEGA formulations QL examples
    INVEGA HAFYERA 1092 mg/3.5MLQL 3.5 ML per 180 days
    INVEGA SUSTENNA 117 mg/0.75MLQL 0.75 ML per 30 days
    inv-154: quetiapine fumarate ER QL example
    Quetiapine fumarate ER 150/200/50 mgQL 30 EA per 30 days
    Quetiapine fumarate ER 300/400 mgQL 60 EA per 30 days
    inv-155: emtricitabine-tenofovir QL examples
    Emtricitabine-tenofovir (selected strengths)QL 30 EA per 30 days
    PREZISTA oral suspensionQL 400 ML per 30 days
    inv-156: PREZISTA oral suspension QL example
    PREZISTA oral suspensionQL 400 ML per 30 days
    PAXLOVID (150/100)QL 40 EA per 180 days
    inv-157: PAXLOVID QL example
    PAXLOVID (150/100)QL 40 EA per 180 days
    PAXLOVID (300/100 & 150/100)QL examples: 22-60 EA per 180 days depending on formulation
    inv-158: OZEMPIC formulations QL/PA examples
    OZEMPIC (0.25/0.5 mg and 1 mg formulations)PA; QL 3 ML per 28 days (pen injector) or QL 30 EA per 30 days depending on formulation
    MOUNJAROPA; QL 2 ML per 28 days
    inv-159: HUMULIN R U-500 KWIKPEN QL example
    HUMULIN R U-500 KWIKPENRequirements/Limits listed (see formulary)
    Insulin syringes (reli-on 29g 0.3ml)PA (pen/needle supplies may be PA)
    inv-160: SOLIQUA QL example
    SOLIQUAQL 15 ML per 25 days
    Enoxaparin 40 mg/0.4ml prefilled syringeQL 24 ML per 30 days
    inv-161: enoxaparin 30 mg/0.3ml QL example
    Enoxaparin 30 mg/0.3ml prefilled syringeQL 18 ML per 30 days
    Enoxaparin 60 mg/0.6ml prefilled syringeQL 36 ML per 30 days
    inv-162: enoxaparin 40 mg/0.4ml QL example
    Enoxaparin 40 mg/0.4ml prefilled syringeQL 24 ML per 30 days
    Fondaparinux 10 mg/0.8mlQL 24 ML per 30 days
    inv-163: enoxaparin 60 mg/0.6ml QL example
    Enoxaparin 60 mg/0.6ml prefilled syringeQL 36 ML per 30 days
    Fondaparinux 5 mg/0.4mlQL 12 ML per 30 days
    inv-164: XARELTO oral suspension QL example
    XARELTO oral suspension (reconstituted)QL 620 ML per 30 days
    XARELTO oral tablet 10 mgQL 30 EA per 30 days
    inv-165: ELIQUIS QL examples — pack-dependent ranges
    ELIQUIS (pack-dependent)examples: QL 30–592 EA per 30 days depending on pack
    Dabigatran etexilate mesylateQL 60 EA per 30 days
    inv-166: eltrombopag QL examples
    Eltrombopag (various strengths/forms)examples: QL 30–180 EA per 30 days depending on strength/form
    PREZISTA oral tablet 150 mgQL 240 EA per 30 days
    inv-167: ACE inhibitor tablets QL examples
    Multiple ACE inhibitor tablets (examples)QL examples: 30, 60, 120, 240, 480 EA per 30 days depending on product
    Candesartan cilexetil 4 mgQL 240 EA per 30 days
    inv-168: Multiple QL examples — assorted QLs across the formulary
    Assorted QL examples (selected)See per-drug entries for specific QL units (EA, ML, GM) and timeframes; examples include 136 ML/10 days, 600 ML/30 days, 500 ML/30 days
    DIFICIDST; QL 136 ML per 10 days (suspension) or QL 20 EA per 10 days (tablet)
    BrivaracetamPA; QL 600 ML per 30 days (solution) or QL 60 EA per 30 days (tablet)
    inv-169: methylphenidate 10 mg/5ml oral solution QL example
    Methylphenidate HCl oral solution 10 mg/5mlQL 1500 ML per 30 days
    Methylphenidate HCl oral solution 5 mg/5mlQL 3000 ML per 30 days
    Methylphenidate oral tabletsQL examples: 30–90 EA per 30 days depending on formulation
    inv-170: methylphenidate 5 mg/5ml oral solution QL example
    Methylphenidate HCl oral solution 5 mg/5mlQL 3000 ML per 30 days
    Methylphenidate ER tablets 27/36 mgQL 60 EA per 30 days
    inv-171: AUSTEDO 12 mg QL example
    AUSTEDO oral tablet 12 mgPA; QL 120 EA per 30 days
    AUSTEDO oral tablet 6 mgPA; QL 60 EA per 30 days
    inv-172: AUSTEDO 6 mg QL example
    AUSTEDO oral tablet 6 mgPA; QL 60 EA per 30 days
    AUSTEDO XRPA; QL 30 EA per 30 days
    inv-173: RADICAVA ORS QL example
    RADICAVA ORSPA; QL 70 ML per 28 days
    RADICAVA ORS starter kitPA; QL 70 ML per 28 days
    inv-174: AVONEX QL example
    AVONEX PEN / AVONEX prefilled syringePA; QL 4 EA per 28 days
    BETASERON subcutaneous kitPA; QL 15 EA per 30 days
    inv-175: DUPIXENT QL examples
    DUPIXENT (200 mg / 300 mg)PA; QL 3.42 ML per 30 days (200 mg) or 8 ML per 30 days (300 mg)
    DUPIXENT 100 mg/0.67mlPA; QL 1.34 ML per 30 days
    inv-176: COSENTYX QL example
    COSENTYX SENSOREADY (300 mg)PA; QL 8 ML per 28 days
    COSENTYX prefilled syringe 75 mg/0.5mlPA; QL 2 ML per 28 days
    inv-177: SKYRIZI cartridge QL example
    SKYRIZI cartridge 180 mg/1.2mlQL 1.2 ML per 56 days
    SKYRIZI cartridge 360 mg/2.4mlQL 2.4 ML per 56 days
    inv-178: adalimumab-adaz presentations QL examples
    Adalimumab-adaz 40 mg/0.4mlPA; QL 2.4 ML per 28 days
    Adalimumab-adaz 10 mg/0.1mlPA; QL 0.2 ML per 28 days
    inv-179: ICATIBANT QL example
    ICATIBANT (icatibant acetate)QL 18 ML per 30 days
    Lanreotide acetateRequirements/Limits listed (see formulary)
    inv-180: adalimumab-adaz 40 mg/0.4ml QL example
    Adalimumab-adaz 40 mg/0.4mlPA; QL 2.4 ML per 28 days
    ENBREL subcutaneous solution 25 mg/0.5mlPA; QL 8 ML per 28 days
    inv-181: ENBREL subcutaneous solution QL example
    ENBREL subcutaneous solution 25 mg/0.5mlPA; QL 8 ML per 28 days
    HADLIMA Pushtouch 40 mg/0.4mlPA; QL 2.4 ML per 28 days
    inv-182: HADLIMA PUSHTOUCH QL example
    HADLIMA Pushtouch 40 mg/0.4mlPA; QL 2.4 ML per 28 days
    HADLIMA 40 mg/0.8mlPA; QL 4.8 ML per 28 days
    inv-183: OTEZLA QL example
    OTEZLA oral tablet 20 mgPA; QL 60 EA per 30 days
    OTEZLA therapy packPA; QL 55 EA per 28 days
    inv-184: bacitracin-polymyxin ophthalmic ointment QL example
    Bacitracin-polymyxin ophthalmic ointmentQL 7 GM per 30 days
    Erythromycin ophthalmicQL 21 GM per 30 days
    inv-185: erythromycin ophthalmic QL example
    Erythromycin ophthalmicQL 21 GM per 30 days
    Gentamicin sulfate ophthalmic solutionQL 30 ML per 30 days
    inv-186: gentamicin ophthalmic solution QL example
    Gentamicin sulfate ophthalmic solutionQL 30 ML per 30 days
    Moxifloxacin HCl ophthalmic solutionQL 12 ML per 30 days
    inv-187: moxifloxacin ophthalmic solution QL example
    Moxifloxacin HCl ophthalmic solutionQL 12 ML per 30 days
    Ketorolac tromethamine ophthalmic solution 0.5%QL 20 ML per 30 days
    inv-188: ketorolac ophthalmic solution QL example
    Ketorolac tromethamine ophthalmic solution 0.5%QL 20 ML per 30 days
    Epinephrine auto-injectorQL 4 EA per 30 days
    inv-189: epinephrine auto-injector QL example
    Epinephrine injection auto-injectorQL 4 EA per 30 days
    BREYNA (inhaled)QL 10.3 GM per 30 days
    inv-190: KALYDECO QL example
    KALYDECOPA; QL 56 EA per 28 days
    TRIKAFTA therapy packPA; QL 84 EA per 28 days (or 56 EA per 28 days alternate listing)
    inv-191: PULMOZYME designation — B/D noted for inhalation solution
    PULMOZYME inhalation solution 2.5 mg/2.5mlB/D designation (Part B vs Part D)
    CAYSTONPA; LA
    inv-192: TRIKAFTA therapy pack QL example
    TRIKAFTA oral tablet therapy packPA; QL 84 EA per 28 days (or 56 EA per 28 days)
    ORKAMBIPA; QL 60 or 120 EA per 30 days depending on listing
    inv-193: ADEMPAS QL example
    ADEMPASPA; QL 90 EA per 30 days
    ORENITRAM Month 1PA; QL 168 EA per 28 days
    inv-194: ORENITRAM MONTH 1 QL example
    ORENITRAM Month 1PA; QL 168 EA per 28 days
    Sildenafil citrate 20 mgPA; QL 90 EA per 30 days
    inv-195: sildenafil citrate 20 mg QL example
    Sildenafil citrate 20 mgPA; QL 90 EA per 30 days
    Tadalafil (PAH)PA; QL 60 EA per 30 days
    inv-196: FASENRA QL example
    FASENRA pen / prefilled syringe 30 mg/mlPA; QL 1 ML per 30 days
    TRELEGY ELLIPTAQL 60 EA per 30 days
    inv-197: TRELEGY ELLIPTA QL example
    TRELEGY ELLIPTAQL 60 EA per 30 days
    BREO ELLIPTAQL 60 EA per 30 days

    Definitions & Abbreviations

    inv-99: Biosimilar / interchangeable biosimilar definition
    Biosimilar definitionBiosimilar: alternative to original biological product; interchangeable biosimilars may be substituted per state law
    Substitution ruleInterchangeable biosimilars may be substituted without a new prescription depending on state laws
    inv-100: B/D definition — Part B vs Part D designation note
    B/D designationIndicates Part B vs Part D; drug may require provider-submitted information about use/setting to determine coverage
    Examples notedPULMOZYME and some erythropoiesis-stimulating agents are listed with B/D designation
    inv-101: ED (Excluded Drug) definition — what ED means for coverage
    ED — Excluded DrugExcluded Drug: not normally covered in a Medicare Prescription Drug Plan; costs do not count toward catastrophic coverage
    Plan exceptionsOnly Priority Medicare Thrive and Thrive Plus plans offer coverage for excluded drugs
    inv-104: HI definition — Home Infusion / medical benefit note
    HI — Home InfusionHome Infusion: drug may be covered under medical benefit; contact Customer Care for details
    ExamplesSome IV/infusion products are flagged HI and may require home infusion or infusion center setting
    inv-105: Tier definitions — T1 through T5 meaning
    Tier definitions (T1–T5)T1 Preferred generic; T2 Generic; T3 Preferred brand; T4 Non-preferred; T5 Specialty (Tier 5 drugs are 30-day supply only)
    Supply noteTier 5 drugs are 30-day supply only (note appears in legend)
    inv-106: Abbreviations list — common abbreviations used in the formulary
    Common abbreviationsPA = Prior Authorization; QL = Quantity Limits; ST = Step Therapy; HI = Home Infusion; EA = Each; ML = Milliliters; GM = Grams
    Other codesB/D = Part B vs Part D; ED = Excluded Drug; LA = Limited Availability; NE = No Express Scripts
    inv-107: Abbreviation legend — PA, QL, ST, HI, LA, NE explained with tiers
    Abbreviation legend (short forms)PA = Prior Authorization; QL = Quantity Limits; ST = Step Therapy; HI = Home Infusion; LA = Limited Availability; NE = No Express Scripts; EA = Each; ML = Milliliters; GM = Grams
    Tier noteT1–T5 tier labels are included in legend; Tier 5 = Specialty
    inv-108: PA short form definition
    PA (Prior Authorization)Prior Authorization: coverage requires approval from Priority Health Medicare before dispensing
    Provider actionProviders must obtain PA to avoid coverage denial
    inv-109: QL short form definition
    QL (Quantity Limits)Quantity Limits: maximum allowed quantity per specified time period as listed for each drug
    Units usedUnits include EA (Each), ML (Milliliters), GM (Grams)
    inv-110: T5 short form definition — Specialty tier
    T5 — Specialty tierTier 5: Specialty — drugs typically subject to PA and QL; 30-day supply only
    ImplicationMany Tier 5 agents require prior authorization and have specified quantity limits
    inv-111: Abbreviation key — listing of common abbreviations
    Abbreviation key summaryLists abbreviations used across the formulary: PA, QL, ST, HI, LA, B/D, EA, ML, GM, ED, NE
    Reference pageAbbreviation meanings available beginning on page 9 of the formulary
    inv-112: Abbreviations — additional definitions and notes
    Abbreviations definedPA = Prior Authorization; QL = Quantity Limits; ST = Step Therapy; HI = Home Infusion; B/D = Part B vs Part D; EA = Each; ML = Milliliters; GM = Grams
    UsageThese abbreviations indicate utilization management and units for quantity limits
    inv-113: Abbreviations legend — B/D, EA, ED, HI, LA, NE explained with tiers
    Abbreviations legend (detailed)B/D - Part B vs Part D; EA - Each; ED - Excluded Drug; HI - Home Infusion; LA - Limited Availability; NE - No Express Scripts; PA - Prior Authorization; QL - Quantity Limits; ST - Step Therapy; ML - Milliliters; GM - Grams
    Tier supply noteNote: Tier 5 drugs are 30-day supply only
    inv-114: Tier definitions — T1-T5 and Tier 5 supply note
    Tier definitions (T1–T5)T1 Preferred generic; T2 Generic; T3 Preferred brand; T4 Non-preferred; T5 Specialty
    Supply duration noteTier 5 drugs are 30-day supply only
    inv-115: PA definition — Prior Authorization coverage requirement
    PA — Prior AuthorizationCoverage requires approval before dispensing when 'PA' is listed
    QL — Quantity LimitsWhen 'QL' is listed the drug is limited to the specified quantity per timeframe
    inv-116: QL definition — Quantity Limits definition
    QL definitionQuantity Limits — maximum allowed quantity per specified time period as shown per product entry
    Example unitsExamples include EA (Each), ML (Milliliters), GM (Grams)
    inv-117: B/D definition — Part B vs Part D designation
    B/D designationPart B vs Part D designation — may affect coverage channel and require provider documentation to determine payment/benefit
    ExamplesPULMOZYME and some erythropoiesis-stimulating agents are designated B/D in the formulary
    inv-118: Tiers — formulary tier definitions (T1-T5)
    Tiers (summary)T1 Preferred generic; T2 Generic; T3 Preferred brand; T4 Non-preferred drug; T5 Specialty
    Tier 5 supply ruleTier 5 (Specialty) drugs are 30-day supply only
    inv-119: Tiers repeated — T1-T5 tier list
    Tier listing repeatedFormulary uses T1–T5 tier scheme with T5 as Specialty
    Refer to legendSee page 9 for abbreviation meanings and tier details

    Biosimilars & Substitution

    Documentation Required

    Include required documentation for biologic PA submissions

    When submitting prior authorization requests for PA‑coded biologics, include the specific documentation referenced by the formulary entry (clinical rationale, prior treatments, and any required site‑of‑care details) to support approval.

    • Biologic entries (adalimumab‑adaz, ENBREL, DUPIXENT, COSENTYX) require PA and list QL; include dosing/presentation and clinical history in the PA request.

    Background Notes

    Biological products are distinct from traditional small‑molecule generics; the formulary notes that biosimilars are alternatives to original biologic products and that interchangeable biosimilars may be substituted per applicable state law. The plan may add certain biosimilars (including interchangeable biosimilars) and substitute them for the original biological product without advance notice to affected members; prescribers or members may request an exception when warranted.

    Additional Coding & Legend Notes

    Selected product presentationsNDC/formulation
    45 mg/0.5mlustekinumab-aekn subcutaneous solution prefilled syringe 45 mg/0.5ml
    90 mg/mlustekinumab-aekn subcutaneous solution prefilled syringe 90 mg/ml
    200 mg/1.14mlDUPIXENT subcutaneous solution auto-injector 200 mg/1.14ml
    300 mg/2mlDUPIXENT subcutaneous solution auto-injector 300 mg/2ml
    75 mg/0.5mlCOSENTYX subcutaneous solution prefilled syringe 75 mg/0.5ml